ANGPTL8 Antibody

中文名稱：

ANGPTL8兔多克隆抗體
貨號：

CSB-PA757793LA01HU
規格：

￥440
圖片：
Immunohistochemistry of paraffin-embedded human liver tissue using CSB-PA757793LA01HU at dilution of 1:100
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) ANGPTL8 Polyclonal antibody
Uniprot No.：

Q6UXH0
基因名：

ANGPTL8
別名：

ANGPTL8 antibody; C19orf80 antibody; RIFL antibody; UNQ599/PRO1185Angiopoietin-like protein 8 antibody; Betatrophin antibody; Lipasin antibody; Refeeding-induced fat and liver protein antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Angiopoietin-like protein 8 protein (22-198AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，ANGPTL8 Antibody (CSB-PA757793LA01HU)，的標記方式是Non-conjugated。對于ANGPTL8 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA757793LB01HU	ANGPTL8 Antibody, HRP conjugated	ELISA
FITC	CSB-PA757793LC01HU	ANGPTL8 Antibody, FITC conjugated
Biotin	CSB-PA757793LD01HU	ANGPTL8 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Hormone that acts as a blood lipid regulator by regulating serum triglyceride levels. May be involved in the metabolic transition between fasting and refeeding: required to direct fatty acids to adipose tissue for storage in the fed state.
基因功能參考文獻：
1. ANGPTL8 levels are lower in Prader-Willi syndrome than obese controls and are inversely associated with the severity of liver steatosis. Further studies should investigate the potential genetic basis for this observation. PMID: 28600576
2. Inhibition of miR-143-3p amplified ANGPTL8 response to treatments (glucose, insulin, Lipopolysaccharides), suggesting that the miRNA acts to suppress ANGPTL8 expression under metabolically distorted conditions. PMID: 30261196
3. Study suggests that ANGPTL8 levels in early pregnancy are significantly and independently associated with risk of GDM at 24-28 weeks of gestation. PMID: 29167926
4. Circulating full-length ANGPTL8 concentrations in patients with dyslipidemia were significantly elevated as compared to controls. PMID: 30021605
5. ApoCIII may mediate the effects of ANGPTL8 on triglyceride metabolism. PMID: 30021607
6. Study shows that angiopoietin-like protein 8 (ANGPTL-8) was positively correlated with hepatocellular lipid content independent of obesity and insulin resistance, indicating that ANGPTL-8 might be a new and important important predictor of the severity of non-alcoholic fatty liver disease. PMID: 29266821
7. We conclude that serum betatrophin concentrations were increased in pregnancies affected by hyperemesis gravidarium. PMID: 29754072
8. Data suggest the angiopoietin-like 8 (ANGPTL8)/p62-IKKgamma axis as a negative feedback loop that regulates NF-kappaB activation, and extends the role of selective autophagy in fine-tuned inflammatory responses. PMID: 29255244
9. ANGPTL8 levels are increased in both plasma and adipose tissues of subjects with hypertension. PMID: 29490644
10. Serum ANGPTL8 concentrations were significantly increased in impaired glucose regulation and type 2 diabetes. PMID: 29082263
11. the level of circulating betatrophin is positively associated with insulin resistance. PMID: 28931172
12. we identified ANGPTL8 as the target gene at this HDL-C GWAS locus, determined regulatory drivers of tissue specificity, and combined fine-mapping approaches and regulatory overlap with experimental assays to identify variants that may contribute to the HDL-C GWAS signal at ANGPTL8. PMID: 28754724
13. serum levels not associated with weight status, glucose tolerance, insulin resistance, or lipid metabolism PMID: 27402552
14. Elevated betatrophin levels in polycystic ovary syndrome women, in the absence of obesity and glucose intolerance, may reflect a compensatory mechanism in order to counteract metabolic syndrome-related risk factors. PMID: 28319674
15. betatrophin levels appeared to be related to the pathogenesis of the diabetic stages rather than prediabetic stages. PMID: 28351091
16. Angiopoietin-like protein 8/betatrophin is related to liver steatosis, while visceral adipose tissue represents an additional site of expression in humans. PMID: 28351093
17. ANGPTL8 reverses established Adriamycin induced cardiomyopathy by stimulating adult cardiac progenitor cells. PMID: 27823982
18. Study provided an update to understand its physiological function from literature curated findings through an integrated view of ANGPTL8's regulation and its associated pathways. PMID: 28684091
19. betatrophin is increased in pancreatic cancer-associated diabetes PMID: 27276680
20. These results confirm a role for ANGPTL8 in lipoprotein metabolism and provide novel support for functional consequences of the rs2278426 variant. PMID: 27117576
21. ANGPTL8 has a functional LPL inhibitory motif, but only inhibits LPL and increases plasma TG levels in mice in the presence of ANGPTL3 PMID: 28413163
22. The inflammation-induced miR-221-3p regulates ANGPTL8 expression in adipocytes. This miRNA impact may become especially prominent under pathologic conditions such as morbid obesity, putatively contributing to the impaired adipose tissue lipid metabolism in metabolic disease. PMID: 28938482
23. Circulating ANGPTL8 increases after bariatric surgery and predicts type 2 diabetes remission in morbidly obese patients. PMID: 28347650
24. Data suggest that plasma betatrophin levels are significantly increased in lean (normal-weight) women with PCOS (polycystic ovary syndrome) compared to lean women without PCOS; plasma betatrophin levels are not significantly altered in overweight/obese women with PCOS compared to overweight/obese women without PCOS. This study was conducted in China. PMID: 27960599
25. Especially the association to eGFR highlights the importance for future studies to address renal function as possible influence on betatrophin regulation and consider eGFR as potential confounder when analyzing the role of betatrophin in humans PMID: 28257453
26. Serum betatrophin is an independent risk factor for nonalcoholic fatty liver and potential non-invasive marker for its progression. PMID: 28125672
27. Cord blood betatrophin may function as a potential biomarker of maternal intrauterine hyperglycemia and fetal insulin resistance, which may presage for long-term metabolic impact of gestational diabetes on offspring PMID: 27196053
28. The high levels of ANGPTL8 found in fetal life together with its relationship with newborn adiposity and brown adipose tissue point to ANGPTL8 as a potential new player in the modulation of the thermogenic machinery during the fetal-neonatal transition. PMID: 27469268
29. Betatrophin levels were increased in women with PCOS and were associated with insulin resistance, c-reactive protein, and free-testosterone in these patients. PMID: 26832343
30. Obesity is associated with increased betatrophin suppression after an oral glucose load; this response appears to be driven by hyperglycemia. Data suggest that the impaired betatrophin response in obese subjects is restored after weight loss and is comparable with the betatrophin response in lean individuals. PMID: 27459526
31. Serum betatrophin levels are increased and associated with insulin resistance in patients with polycystic ovary syndrome. PMID: 28222635
32. ANGPTL8/betatrophin might play an important role in glucose metabolism in the context of insulin resistance. PMID: 26387753
33. This study supports that serum betatrophin plays an important role in MetS, involving the regulations of glucose and lipid metabolism and inflammation. PMID: 27238790
34. our data shows that ANGPTL3, 4 and 8 are increased in obesity and type 2 diabetes (T2D). ANGPTL8 associates with ANGPTL3 in the non-diabetic subjects while it associated more with ANGPTL4 in the obese and T2D subjects. PMID: 27733177
35. circulating betatrophin is increased in mice and humans with NAFLD and its expression was induced by endoplasmic reticulum stress in hepatocytes PMID: 27045862
36. High betatrophin expression is associated with diabetic metabolic syndrome. PMID: 27578619
37. Elevated betatrophin levels were associated with cardiometabolic risk factors a young population, but the association was largely dependent on vitamin D status. PMID: 27716289
38. betatrophin may be associated with thyroid insufficiency but not thyroid autoimmunity. PMID: 27213151
39. Betatrophin levels in patients with polycystic ovary syndrome (PCOS) are lower than those without PCOS and inversely related to insulin resistance. PMID: 27188865
40. data shows for the first time that heterozygote form of ANGPTL8 Rs.2278426 variant was associated with higher FBG level in Arabs highlighting the importance of these variants in controlling the function of betatrophin. PMID: 26864934
41. Serum betatrophin concentrations are increased in type 2 diabetes patients under antidiabetic treatment and positively associated with diabetic retinopathy. PMID: 26863068
42. Compared with type 2 diabetes without cardiovascular disease (CVD), patients with CVD had remarkably higher levels of angiopoietin-like protein 8 (ANGPTL8). PMID: 27596060
43. Circulating betatrophin concentration is negatively correlated with insulin resistance in obese children and adolescents. PMID: 27103367
44. Meta-analysis results from case control studies on betatrophin and type 2 diabetes (T2DM) revealed increased circulating levels of betatrophin in patients with T2DM. PMID: 27242389
45. ANGPTL8 levels were associated with baseline and future changes in triglyceride levels in Korean children. PMID: 26739706
46. Betatrophin is significantly increased in T2DM patients with different stages of albuminuria. Betatrophin may be a novel endocrine regulator involved in DN development. PMID: 26739836
47. ANGPTL8 is increased in subjects with MetS and it was significantly associated with HsCRP levels in different subgroups. PMID: 26850725
48. Disruption of ANGPTL8 function in humans does not seem to have a large effect on measures of glucose tolerance. PMID: 26822414
49. Based on the findings of our meta-analysis, circulating betatrophin level of T2DM patients is higher than that of nondiabetic adults in the nonobese population, but not in the obese population. PMID: 26697500
50. In patients with diabetes mellitus type 2, betatrophin levels did not correlate with beta-cell function-related variables or insulin resistance-related variables PMID: 26649318
顯示更多

收起更多
相關疾病：

Diabetes mellitus, insulin-dependent (IDDM); Diabetes mellitus, non-insulin-dependent (NIDDM)
亞細胞定位：

Secreted.
蛋白家族：

ANGPTL8 family
組織特異性：

Predominantly expressed in liver. Also expressed in adipose tissues.
數據庫鏈接：

HGNC: 24933

OMIM: 125853

KEGG: hsa:55908

STRING: 9606.ENSP00000252453

UniGene: Hs.534467

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human